DC Field | Value | Language |
---|---|---|
dc.contributor.author | E Kim | - |
dc.contributor.author | Jeong Gu Kang | - |
dc.contributor.author | M J Kang | - |
dc.contributor.author | J H Park | - |
dc.contributor.author | Y J Kim | - |
dc.contributor.author | T H Kweon | - |
dc.contributor.author | H W Lee | - |
dc.contributor.author | E H Jho | - |
dc.contributor.author | Y H Lee | - |
dc.contributor.author | S I Kim | - |
dc.contributor.author | E C Yi | - |
dc.contributor.author | H W Park | - |
dc.contributor.author | W H Yang | - |
dc.contributor.author | J W Cho | - |
dc.date.accessioned | 2020-09-24T03:39:49Z | - |
dc.date.available | 2020-09-24T03:39:49Z | - |
dc.date.issued | 2020 | - |
dc.identifier.issn | 0027-8424 | - |
dc.identifier.uri | https://oak.kribb.re.kr/handle/201005/22724 | - |
dc.description.abstract | The Hippo pathway controls organ size and tissue homeostasis by regulating cell proliferation and apoptosis. The LATS-mediated negative feedback loop prevents excessive activation of the effectors YAP/TAZ, maintaining homeostasis of the Hippo pathway. YAP and TAZ are hyperactivated in various cancer cells which lead to tumor growth. Aberrantly increased O-GlcNAcylation has recently emerged as a cause of hyperactivation of YAP in cancer cells. However, the mechanism, which induces hyperactivation of TAZ and blocks LATS-mediated negative feedback, remains to be elucidated in cancer cells. This study found that in breast cancer cells, abnormally increased O-GlcNAcylation hyperactivates YAP/TAZ and inhibits LATS2, a direct negative regulator of YAP/TAZ. LATS2 is one of the newly identified O-GlcNAcylated components in the MST-LATS kinase cascade. Here, we found that O-GlcNAcylation at LATS2 Thr436 interrupted its interaction with the MOB1 adaptor protein, which connects MST to LATS2, leading to activation of YAP/TAZ by suppressing LATS2 kinase activity. LATS2 is a core component in the LATS-mediated negative feedback loop. Thus, this study suggests that LATS2 O-GlcNAcylation is deeply involved in tumor growth by playing a critical role in dysregulation of the Hippo pathway in cancer cells. | - |
dc.publisher | Natl Acad Sciences | - |
dc.title | O-GlcNAcylation on LATS2 disrupts the Hippo pathway by inhibiting its activity | - |
dc.title.alternative | O-GlcNAcylation on LATS2 disrupts the Hippo pathway by inhibiting its activity | - |
dc.type | Article | - |
dc.citation.title | Proceedings of National Academy of Sciences of United States of America | - |
dc.citation.number | 25 | - |
dc.citation.endPage | 14269 | - |
dc.citation.startPage | 14259 | - |
dc.citation.volume | 117 | - |
dc.contributor.affiliatedAuthor | Jeong Gu Kang | - |
dc.contributor.alternativeName | 김은아 | - |
dc.contributor.alternativeName | 강정구 | - |
dc.contributor.alternativeName | 강민정 | - |
dc.contributor.alternativeName | 박재형 | - |
dc.contributor.alternativeName | 김연정 | - |
dc.contributor.alternativeName | 권태현 | - |
dc.contributor.alternativeName | 이한웅 | - |
dc.contributor.alternativeName | 조억훈 | - |
dc.contributor.alternativeName | 이용호 | - |
dc.contributor.alternativeName | 김승일 | - |
dc.contributor.alternativeName | 이유진 | - |
dc.contributor.alternativeName | 박현우 | - |
dc.contributor.alternativeName | 양원호 | - |
dc.contributor.alternativeName | 조진원 | - |
dc.identifier.bibliographicCitation | Proceedings of National Academy of Sciences of United States of America, vol. 117, no. 25, pp. 14259-14269 | - |
dc.identifier.doi | 10.1073/pnas.1913469117 | - |
dc.subject.keyword | Hippo pathway | - |
dc.subject.keyword | LATS2 | - |
dc.subject.keyword | MOB1 | - |
dc.subject.keyword | O-GlcNAcylation | - |
dc.subject.keyword | cancer | - |
dc.subject.local | Hippo pathway | - |
dc.subject.local | LATS2 | - |
dc.subject.local | MOB1 | - |
dc.subject.local | O-GlcNAcylation | - |
dc.subject.local | Cancers | - |
dc.subject.local | cancer | - |
dc.subject.local | Cancer | - |
dc.description.journalClass | Y | - |
There are no files associated with this item.
Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.